LGALS3 and infection: Evidence from multiple studies demonstrates that myeloid cell-derived Gal3 drives acute and chronic inflammation, including infection-mediated inflammation, and warrants further evaluation of Gal3 as a therapeutic target (Ferreira et al., 2018; Wang et al., 2019; Chiu et al., 2020; Guo et al., 2021; Humphries et al., 2021).